#1 Clinical Trials Search in Europe

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

3 1

What is this study about?

This clinical trial is focused on studying the effects of a treatment called Maridebart Cafraglutide in adults who are either overweight or have obesity but do not have Type 2 Diabetes Mellitus. The main goal of the study is to see if Maridebart Cafraglutide can help reduce body weight more effectively than a placebo. Maridebart Cafraglutide is a solution for injection and is also known by its code name, AMG 133. It is a type of protein that combines a monoclonal antibody with a peptide, which is a small protein-like chain.

Participants in the study will receive either Maridebart Cafraglutide or a placebo and will be monitored over a period of 72 weeks. The study will track changes in body weight, waist circumference, and other health indicators such as blood pressure and fasting glucose levels. The aim is to observe the percentage change in body weight and other health improvements over this time.

The study is designed to help understand how effective and safe Maridebart Cafraglutide is for managing weight in people without Type 2 Diabetes Mellitus. By the end of the study, researchers hope to gather valuable information on how this treatment can aid in chronic weight management and improve the quality of life for those who are overweight or have obesity.

1 joining the study

Upon joining the study, informed consent is required. This means agreeing to participate after understanding the study’s purpose and procedures.

Eligibility is confirmed based on criteria such as age, body mass index (BMI), and medical history related to weight management.

2 initial assessment

An initial assessment is conducted to record baseline measurements. This includes body weight, waist circumference, and other health indicators.

Participants are asked to maintain lifestyle logs and follow lifestyle advice provided by the study team.

3 medication administration

Participants receive either the study medication, maridebart cafraglutide, or a placebo. The medication is administered as a solution for injection under the skin (subcutaneous use).

The frequency and dosage of the medication are determined by the study protocol and are administered regularly throughout the study duration.

4 ongoing monitoring

Regular follow-up visits are scheduled to monitor progress. These visits include measurements of body weight, waist circumference, and other health indicators.

Participants complete questionnaires about their quality of life and physical function.

5 final assessment

At the end of the study period, a final assessment is conducted. This includes measuring changes in body weight, waist circumference, and other health indicators.

The study aims to evaluate the percentage change in body weight and other health outcomes over a period of 72 weeks.

Who Can Join the Study?

  • The participant must have given their agreement to join the study by signing a consent form.
  • The participant must be at least 18 years old or older, depending on the legal age in their country.
  • The participant must have a Body Mass Index (BMI) of 30 or higher. BMI is a measure of body fat based on height and weight.
  • If the participant’s BMI is between 27 and 30, they must have at least one of the following health conditions related to weight:
    • Hypertension: High blood pressure, either treated or with a systolic blood pressure (SBP) of 130 or higher, or a diastolic blood pressure (DBP) of 80 or higher.
    • Dyslipidemia: Abnormal levels of fats in the blood, either treated or with:
      • Low-density lipoprotein (LDL) of 160 or higher.
      • Triglycerides of 150 or higher.
      • High-density lipoprotein (HDL) less than 40 for males or less than 50 for females.
    • Obstructive sleep apnea: A condition where breathing stops and starts during sleep.
    • Cardiovascular disease: Heart-related conditions, such as ischemic heart disease or heart failure classified as New York Heart Association (NYHA) Class I, II, or III.
    • Metabolic dysfunction-associated steatotic liver disease: A liver condition related to metabolism issues.
  • The participant must have tried at least once to lose weight through diet and exercise without success.
  • The participant must be considered by the study investigator to be motivated and willing to follow the study procedures, which include following lifestyle advice, keeping a lifestyle log, and attending all required study visits and completing questionnaires.

Who Cannot Join the Study?

  • Patients who are not within the specified age range for the study.
  • Patients who are part of a vulnerable population, which means groups that might need special protection or care.
  • Patients who have medical conditions other than Chronic Weight Management that might interfere with the study.
  • Patients who are not able to follow the study procedures or instructions.
  • Patients who are currently participating in another clinical trial.
  • Patients who have a history of allergic reactions to the study medication or similar medications.
  • Patients who are pregnant or breastfeeding.
  • Patients with certain medical conditions that the study doctors believe would make it unsafe for them to participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Uniwersyteckie Centrum Kliniczne Im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego W Katowicach Katowice Poland
Azienda Ospedaliero Universitaria Careggi Florence Italy
Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A. Lodz Poland
Praxis für Prävention und Therapie Prof. Dr. med. Stephan Jacob Villingen-Schwenningen Germany
MVZ DiaMedicum Bad Mergentheim GmbH Bad Mergentheim Germany
Endokrinologikum Hamburg Hamburg Germany
Diabeteszentrum Hamburg West Hamburg Germany
Universitaet Leipzig Leipzig Germany
Health Step Finland Oy Kuopio Finland
Futuremeds Sp. z o.o. Wroclaw Poland
Technische Universitaet Dresden Dresden Germany
Katholieke Universiteit te Leuven Leuven Belgium
Hospital Universitario De Navarra Pamplona Spain
Diabetespraxis Dr. Braun Berlin Germany
Policlinico “Tor Vergata”, Università degli Studi di Roma TOR VERGATA Rome Italy
Praxis am Markt Essen Germany
Zentrum für klinische Studien Alexander Segner St. Ingbert Germany
Centrum Zdrowia Metabolicznego Paweł Bogdański Poznan Poland

Other Sites

Site Name City Country Status
Sanos A/S Gandrup Denmark
Centro Cardiologico Monzino S.p.A. Milan Italy
ASST Fatebenefratelli Sacco Milan Italy
Centre hospitalier universitaire de Liege Liege Belgium
PreventaMed s.r.o. Olomouc Czechia
Herz Und Diabeteszentrum NRW Bad Oeynhausen Universitaetsklinik Der Ruhr-Universitaet Bochum Bad Oeynhausen Germany
Universitair Ziekenhuis Gent Gent Belgium
Universitaetsklinikum Aachen AöR Aachen Germany
Algemeen Ziekenhuis Groeninge Kortrijk Belgium
Hospital Universitario Dr Peset Aleixandre Valencia Spain
Ambenet GmbH Das Ambulante Behandlungsnetz Leipzig Germany
CCR Ostrava s.r.o. Moravska Ostrava A Privoz Czechia
Clinical Research Center Sp. z o.o. Medic-R sp.k. Poznan Poland
Hospital Virgen Del Camino Sanlucar De Barrameda Spain
B. Braun Ambulantes Herzzentrum Kassel MVZ GmbH Kassel Germany
Pohjois-Pohjanmaan hyvinvointialue Oulu Finland
Endokrinologie Cerny Most s.r.o. Prague Czechia
Endohope klinika s.r.o. Prague Czechia
InnoDiab Forschung GmbH Essen Germany
R.E.D. Institut fuer medizinische Studien und Fortbildung GmbH Oldenburg In Holstein Germany
Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR Berlin Germany
Marienhaus Klinikum Mainz GmbH Mainz Germany
Steno Diabetes Center Copenhagen Herlev Denmark
Kresmed Sp. z o. o. Ostrow Mazowiecka Poland
Universitaetsklinikum Schleswig-Holstein AöR Kiel Germany
Medicus Services s.r.o. Brandys Nad Labem Czechia
ClinPhenomics CVC GmbH Frankfurt Germany
Charite Universitaetsmedizin Berlin KöR Berlin Germany
Fakultni Nemocnice Brno Brno Czechia
Fakultni Nemocnice Kralovske Vinohrady Prague Czechia
Universita’ Di Pisa Pisa Italy
Hospital Ruber Juan Bravo Madrid Spain
Medical Center – University Of Freiburg Freiburg Im Breisgau Germany
Klinische Forschung Berlin GbR Berlin Germany
Zentrum fuer klinische Studien Suedbrandenburg GmbH Elsterwerda Germany
Region Midtjylland Aarhus Denmark
Vseobecna Fakultni Nemocnice V Praze Prague Czechia
Salvia Lekston I Madej Sp. J. Katowice Poland
Gentofte Hospital Hellerup Denmark
CHU Helora La Louviere Belgium
Clinical Best Solutions Sp. z o.o. S.K. Lublin Poland
Zentrum für Klinische Forschung Allgäu Oberschwaben Wangen im Allgäu Germany
Institut fuer Diabetesforschung Muenster GmbH Munster Germany
Instituto Medico Quirurgico San Rafael S.A. A Coruna Galicia Spain
Esozry Sve z ocxq Lublin Poland
Itwhncsyb Fdq Crqddwbn Ayq Eaugfhrkhijp Mmetzwej Prague Czechia
Ediswgjn Hezuteg sankaz Havirov Czechia
Evlsmgj Mechelen Belgium
Piqdiru phgpomma od Dg Timypwctos Markkleeberg Germany
Esx Lwsmam Sgw z oohf Debica Poland
Ceotmws Jfsnips Srmo Palma Spain
Gavdbya Lljrqcem Ohwfixgv i Cgedga Debgvszgjelezu Bialystok Poland
Dkjgvmfc Spnldxokaphgoanix Falkensee Germany
Hrwrxs Hloathju Herlev Denmark
Howcrzbf Umydeykaco Caimdis Hsjjrckk Helsinki Finland
Aklvxmb Udeia Shwsvknkd Lycybd Dq Bucrinp Bologna Italy
Ubqsinctbk Oy Ajflehs Edegem Belgium
Zzngwrc fpm kklykhjsq Svyjixb Bve Hnwqrdb Bad Homburg Germany
Ced Sausquyluodeodq Hjfzzjt Munich Germany
Hjrvwtsov &yaya Djacotlizbhkouyzaqaipvmumz Hpbyutinbql Hohenmölsen Germany
Hfaidwdm Ieceman Eychz Huelva Spain
Op khqaqhg awuk Prague Czechia

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not recruiting
27.05.2025
Czechia Czechia
Not recruiting
27.05.2025
Denmark Denmark
Not recruiting
27.05.2025
Finland Finland
Not recruiting
27.05.2025
Germany Germany
Not recruiting
27.05.2025
Italy Italy
Not recruiting
27.05.2025
Poland Poland
Not recruiting
27.05.2025
Spain Spain
Not recruiting
27.05.2025

Trial locations

Investigated drugs:

Maridebart Cafraglutide is a medication being studied for its potential to help people who are overweight or have obesity lose weight. It is not intended for people with type 2 diabetes. The main goal of this medication in the trial is to see if it can help reduce body weight more effectively than a placebo. Participants in the trial will receive this medication to evaluate its safety, how well it works, and how well people can tolerate it. The study aims to show that this medication can lead to a greater percentage of weight loss compared to not taking the active medication.

Investigated diseases:

Obesity – Obesity is a chronic condition characterized by an excessive accumulation of body fat. It develops when there is an imbalance between calories consumed and calories expended, leading to weight gain. Over time, this condition can result in increased body mass index (BMI) and changes in body shape, particularly around the waist. As obesity progresses, it can affect physical mobility and lead to metabolic changes, such as increased blood pressure and altered glucose levels. The condition can also impact quality of life, affecting physical function and overall well-being. Obesity is often associated with other health issues, such as elevated triglycerides and changes in blood sugar levels.

Trial ID:
2024-515524-36-00
Protocol code:
20210181
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Croatia Germany Hungary Poland Portugal +1

  • RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

    Recruiting

    3 1
    Czechia France Germany Hungary Italy Poland +2